Close
Help




JOURNAL

Clinical Medicine Insights: Psychiatry

Agomelatine: Its Role in the Management of Major Depressive Disorder

Submit a Paper


Clinical Medicine Insights: Psychiatry 2012:4 1-23

Review

Published on 20 Nov 2012

DOI: 10.4137/CMPsy.S7989


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Psychiatry

Abstract

Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness; advances or delays in the circadian phase are documented in patients with major depressive disorder (MDD), bipolar disorder, and seasonal affective disorder (SAD). The disturbances in the amplitude and phase of rhythm in melatonin secretion that occur in patients with depression resemble those seen in chronobiological disorders, thus suggesting a link between disturbed melatonin secretion and depressed mood. Based on this, agomelatine, the first MT1/MT2 melatonergic agonist displaying also 5-HT2C serotonergic antagonism, has been introduced as an antidepressant. Agomelatine has been shown to be effective in several animal models of depression and anxiety and it has beneficial effects in patients with MDD, bipolar disorder, or SAD. Among agomelatine's characteristics are a rapid onset of action and a pronounced effectiveness for correcting circadian rhythm abnormalities and improving the sleep/wake cycle. Agomelatine also improves the 3 functional dimensions of depression—emotional, cognitive, and social—thus aiding in the full recovery of patients to a normal life.



Downloads

PDF  (711.89 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Insights: Psychiatry
The LA experience is exactly what an author would wish for. Reviews are high quality and fast, Editors make decisions on the basis of scientific argument, and the production team is friendly and efficient.
Professor Christopher F Sharpley (NSW, Australia)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube